Ann: June 2021 Quarterly Activities Report & 4C, page-17

First 17 Last

Share
Profile

Follow
SkyLimit

345 Posts.

95

30/07/21

12:58

Post #: 54903869
Share

Originally posted by Hottin: ↑

I get that but don't be just negative and tell us what do you see positive hm.

I'm sure you understand that stocks like RNT take time and you're in it or buy later for much higher price... also it depends how many shares you want to have in your porfolio. 100k is easy to buy at any price.

I like what the board is doing and Bevan jumping on board must be for a reason.

Outlook

“Ongoing optimisation of RentPay remains the focus for the September quarter.

We are adding new security functionality and verifications on the front end while also optimising the user experience and features based on customer insights. In parallel we are finalising marketing campaigns to both our existing customer base as well as the broader renter market.

As we’ve consistently indicated, we will only launch broader marketing campaigns once we’re happy that the customer onboarding and the feature set that we have match the planned investment.

“Now that the peak of the RentPay development has passed, some of our capacity can return to enabling the growth opportunities within the rent.com.au platform. We have an extensive product roadmap of new features and products to drive further profitability and help renters during the search phase of their journey. These improvements will also help transition customers to RentPay.

“We have had a strong start to the new financial year, despite lockdowns in several states restricting the ability of renters to move house. Our core business is firing, and we are creating an exciting new product segment with the release of RentPay that is already attracting interest from customers, real estate agents and potential partners. I feel we have never been in a stronger position to deliver upon our vision of reinventing the renting process and thereby delivering significant shareholder value,” concluded Mr Bader.

Expand

I am not sure why you are quoting large parts of the announcement to me?

Personally, i am happy to sit on the sidelines and see where things progress. They are a long way off where they want to be. Having 700 paying rentpay customers is not something that excites me right now. I would be more happy paying a higher SP at a later date once i see proof that the platform is going to succeed. They mentioned in the announcement that challenges are already arising.

RNT Price at posting: 11.0¢ Sentiment: Sell Disclosure: Not Held
5 Upvote

1 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 33 more messages in this thread...

First 17 Last

Add RNT (ASX) to my watchlist

(20min delay)
Last 2.1¢		Change 0.001(5.00%)		Mkt cap ! $15.16M

Open	High	Low	Value	Volume
2.1¢	2.1¢	2.1¢	$2.119K	100.8K

Buyers (Bids)

No.	Vol.	Price($)
1	303172	2.0¢

Sellers (Offers)

Price($)	Vol.	No.
2.1¢	5596	1

View Market Depth

No.	Vol.	Price($)
1	303172	0.020
2	70862	0.019
5	385055	0.018
5	516616	0.017
1	62562	0.016

Price($)	Vol.	No.
0.021	5596	1
0.022	951206	2
0.026	476190	1
0.030	80000	2
0.035	120000	1

Last trade - 14.06pm 07/10/2024 (20 minute delay)

RNT (ASX) Chart

Ann: June 2021 Quarterly Activities Report & 4C, page-17

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: June 2021 Quarterly Activities Report & 4C, page-17

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News